Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 22, 1987 - Issue 3
Submit an article Journal homepage
35
Views
70
CrossRef citations to date
0
Altmetric
Original Article

Clinical Experience of the Tolerance of Mesalazine and Olsalazine in Patients Intolerant of Sulphasalazine

S. S. Rao Gastrointestinal Unit, Royal Hallamshire Hospital, Sheffield, UK
,
P. A. Cann Gastrointestinal Unit, Royal Hallamshire Hospital, Sheffield, UK
&
C. D. Holdsworth Gastrointestinal Unit, Royal Hallamshire Hospital, Sheffield, UK
Pages 332-336 | Received 20 Aug 1986, Accepted 28 Oct 1986, Published online: 08 Jul 2009

Citations (70)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Roxana M Coman, Sarah C Glover & Altin Gjymishka. (2014) Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide – case report and literature review of the side effects of 5-aminosalicylates. Expert Review of Clinical Immunology 10:5, pages 667-675.
Read now
Md. Umar Khan, M. A. Baseer, S. Ranjith Kumar, M. Saravanakumar, A. G. Prasannanjali, P. Badarinadh Gupta, VipinK. Kaushik, VijayK. Handa & Aminul Islam. (2010) Synthesis and Characterization of Metabolites and Potential Impurities of Balsalazide Disodium, an Anti-Inflammatory Drug. Synthetic Communications 40:15, pages 2241-2253.
Read now
Lisbet A Christensen, Sten N. Rasmussen & Steen H. Hansen. (1994) Disposition of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid in fetal and maternal body fluids during treatment with different 5-aminosalicylic acid preparations. Acta Obstetricia et Gynecologica Scandinavica 73:5, pages 399-402.
Read now
S. S. Rao & C. D. Holdsworth. (1988) Influence of Olsalazine and Sulphasalazine on Gastrointestinal Transit. Scandinavian Journal of Gastroenterology 23:sup148, pages 96-100.
Read now
G. Järnerot. (1988) Clinical Tolerance of Olsalazine. Scandinavian Journal of Gastroenterology 23:sup148, pages 21-23.
Read now

Articles from other publishers (65)

Michelle Gonzalez & Michael Stephens. 2023. Pediatric Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease 339 347 .
Sean Hammond, Anna Olsson-Brown, Sophie Grice, Andrew Gibson, Joshua Gardner, Jose Luis Castrejón-Flores, Carol Jolly, Benjamin Alexis Fisher, Neil Steven, Catherine Betts, Munir Pirmohamed, Xiaoli Meng & Dean John Naisbitt. (2022) Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity. Toxicological Sciences 186:1, pages 58-69.
Crossref
Wolfgang Kruis & Mauro Bafutto. 2022. Colonic Diverticular Disease. Colonic Diverticular Disease 235 244 .
Alistair Murray, Tran M Nguyen, Claire E Parker, Brian G Feagan & John K MacDonald. (2020) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2020:8.
Crossref
Alistair Murray, Tran M Nguyen, Claire E Parker, Brian G Feagan & John K MacDonald. (2020) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2020:8.
Crossref
Mahesh Gajendran, Priyadarshini Loganathan, Guillermo Jimenez, Anthony P. Catinella, Nathaniel Ng, Chandraprakash Umapathy, Nathalie Ziade & Jana G. Hashash. (2019) A comprehensive review and update on ulcerative colitis,. Disease-a-Month 65:12, pages 100851.
Crossref
P. Sehgal, J.-F. Colombel, A. Aboubakr & N. Narula. (2018) Systematic review: safety of mesalazine in ulcerative colitis. Alimentary Pharmacology & Therapeutics 47:12, pages 1597-1609.
Crossref
Gaurav B. Nigam, Jimmy K. Limdi & Dipesh H. Vasant. (2018) Current perspectives on the diagnosis and management of functional anorectal disorders in patients with inflammatory bowel disease. Therapeutic Advances in Gastroenterology 11, pages 175628481881695.
Crossref
Michael Stephens & Michelle Gonzalez. 2017. Pediatric Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease 317 324 .
Reena Khanna & John K. Marshall. 2017. Crohn's Disease and Ulcerative Colitis. Crohn's Disease and Ulcerative Colitis 389 397 .
Yijun Wang, Jun Xia, Bartosz Helfer, Chunbo Li & Stefan Leucht. (2016) Valproate for schizophrenia. Cochrane Database of Systematic Reviews 2016:11.
Crossref
Yongjun Wang, Claire E Parker, Brian G Feagan & John K MacDonald. (2016) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews.
Crossref
Yongjun Wang, Claire E Parker, Tania Bhanji, Brian G Feagan & John K MacDonald. (2016) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews.
Crossref
Cristiana Perrotta, Paolo Pellegrino, Eliana Moroni, Clara De Palma, Davide Cervia, Piergiorgio Danelli & Emilio Clementi. (2015) Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug. Gastroenterology Research and Practice 2015, pages 1-9.
Crossref
Brian G. Feagan, Nilesh Chande & John K. MacDonald. (2013) Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used for Induction and Maintenance of Remission in Ulcerative Colitis? Evidence from Cochrane Reviews. Inflammatory Bowel Diseases, pages 1.
Crossref
Michael Stephens & Alisha M. Mavis. 2013. Pediatric Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease 281 288 .
Brian G Feagan & John K MacDonald. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Reena Khanna & John K. Marshall. 2012. Crohn's Disease and Ulcerative Colitis. Crohn's Disease and Ulcerative Colitis 453 466 .
Richard K. Burt, Robert M. Craig, Francesca Milanetti, Kathleen Quigley, Paula Gozdziak, Jurate Bucha, Alessandro Testori, Amy HalversonLarissa Verda, Willem J. S. de Villiers, Borko Jovanovic & Yu Oyama. (2010) Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood 116:26, pages 6123-6132.
Crossref
Asher Kornbluth & David B Sachar. (2010) Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee. American Journal of Gastroenterology 105:3, pages 501-523.
Crossref
Bj?rn Moum. (2008) Which are the 5-ASA compound side effects and how is it possible to avoid them?. Inflammatory Bowel Diseases 14:Supplement, pages S212-S213.
Crossref
Bjrn Moum. (2008) Which are the 5-ASA compound side effects and how is it possible to avoid them?. Inflammatory Bowel Diseases 14, pages S212-S213.
Crossref
Shiang-Ju Kung, Cuckoo Choudhary, Stephen J. McGeady & John R. Cohn. (2006) Lack of cross-reactivity between 5-aminosalicylic acid-based drugs: a case report and review of the literature. Annals of Allergy, Asthma & Immunology 97:3, pages 284-287.
Crossref
Hillel D. Cohen & Kiron M. Das. (2006) The Metabolism of Mesalamine and Its Possible Use in Colonic Diverticulitis as an Anti-inflammatory Agent. Journal of Clinical Gastroenterology 40:Supplement 3, pages S150-S154.
Crossref
Richard Burt, Larissa Verda, I de Kleer & Nico Wulffraat. 2006. Pediatric Hematopoietic Stem Cell Transplantation. Pediatric Hematopoietic Stem Cell Transplantation 449 476 .
Lloyd R Sutherland & John K MacDonald. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Jean Cezard & Jean Hugot. 2006. Paediatric Clinical Pharmacology. Paediatric Clinical Pharmacology 653 660 .
Michael J. Morris, Daniel E. Cole & Patrick F. Allan. (2005) Pulmonary Disease Associated With Inflammatory Bowel Disease. Clinical Pulmonary Medicine 12:4, pages 246-257.
Crossref
Yu Oyama, Robert M. Craig, Ann E. Traynor, Kathleen Quigley, Laisvyde Statkute, Amy Halverson, Mary Brush, Larissa Verda, Barbara Kowalska, Nela Krosnjar, Morris Kletzel, Peter F. Whitington & Richard K. Burt. (2005) Autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease. Gastroenterology 128:3, pages 552-563.
Crossref
Laura E Harrell & Stephen B Hanauer. (2004) Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterology Clinics of North America 33:2, pages 303-317.
Crossref
Philippe Godeberge. (2004) Prise en charge thérapeutique des proctites. Gastroentérologie Clinique et Biologique 28:5, pages 70-74.
Crossref
R M Craig, A Traynor, Y Oyama & R K Burt. (2003) Hematopoietic stem cell transplantation for severe Crohn's disease. Bone Marrow Transplantation 32, pages S57-S59.
Crossref
L Sutherland & JK MacDonald. 1996. The Cochrane Database of Systematic Reviews. The Cochrane Database of Systematic Reviews.
Johanna C. Escher, Jan A. J. M. Taminiau, Edward E. S. Nieuwenhuis, Hans A. Büller & Richard J. Grand. (2003) Treatment of Inflammatory Bowel Disease in Childhood: Best Available Evidence. Inflammatory Bowel Diseases 9:1, pages 34-58.
Crossref
L Sutherland, D Roth, P Beck, G May & K Makiyama. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Robert M Craig. (2002) Autologous hematopoietic stem cell transplantation for Crohn's disease. Autoimmunity Reviews 1:4, pages 244-249.
Crossref
Karen L. Gibbon, Anthony P. Bewley & Kathleen Thomas. (2001) Mesalazine-induced pustular drug eruption. Journal of the American Academy of Dermatology 45:6, pages S220-S221.
Crossref
M.C. Di Paolo, O.A. Paoluzi, R. Pica, F. Iacopini, P. Crispino, M. Rivera, G. Spera & P. Paoluzi. (2001) Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects. Digestive and Liver Disease 33:7, pages 563-569.
Crossref
Sauid Ishaq & Jonathan R. Green. (2001) Tolerability of Aminosalicylates in Inflammatory Bowel Disease. BioDrugs 15:5, pages 339-349.
Crossref
Bodo Stoschus, Monika Meybehm, Ulrich Spengler, Christian Scheurlen & Tilman Sauerbruch. (1997) Cholestasis associated with mesalazine therapy in a patient with Crohn's disease. Journal of Hepatology 26:2, pages 425-428.
Crossref
Lloyd R. Sutherland, Daniel E. Roth & Paul L. Beck. (1997) Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflammatory Bowel Diseases 3:2, pages 65-78.
Crossref
E. ELTON & S. B. HANAUER. (2007) Review article: The medical management of Crohn's disease. Alimentary Pharmacology & Therapeutics 10:1, pages 1-22.
Crossref
J. P. Wright, D. P. Jewell, R. Modigliani & H. Malchow. (2007) A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease. Inflammatory Bowel Diseases 1:4, pages 241-246.
Crossref
B. Aichbichler, Th. Hinterleitner & W. Petritsch. (1995) Diagnostik und Therapie bei verifizierten chronisch entzündlichen DarmerkrankungenVerified inflammatory bowel disease: Diagnosis and treatment. European Surgery 27:3, pages 133-139.
Crossref
J. P. Wright, D. P. Jewell, R. Modigliani & H. Malchow. (1995) A Randomized, Double-Blind, Placebo-Controlled Trial of Olsalazine for Active Crohnʼs Disease. Inflammatory Bowel Diseases 1:4, pages 241-246.
Crossref
J Bellanger, J Cosnes, JP Gendre, L Beaugerie, M Malafosse & Y Le Quintrec. (1994) Traitement de la maladie de Crohn de l'adulte. La Revue de Médecine Interne 15:10, pages 676-689.
Crossref
Flavio M. Habal, Gavin Hui & Gordon R. Greenberg. (1993) Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: Safety and clinical course. Gastroenterology 105:4, pages 1057-1060.
Crossref
G. F. Bonner & W. B. Ruderman. (1993) 5-aminosalicylic acid preparations in the treatment of inflammatory bowel disease. Inflammopharmacology 2:3, pages 247-262.
Crossref
StephenB Hanauer. (1993) Medical therapy of ulcerative colitis. The Lancet 342:8868, pages 412-417.
Crossref
Marc L. Hautekeete, Nadine Bourgeois, Philippe Potvin, Lieve Duville, Hendrik Reynaert, Ghislain Devis, Michael Adler & Günter Klöppel. (1992) Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine. Gastroenterology 103:6, pages 1925-1927.
Crossref
M. H. GIAFFER, C. J. O'BRIEN & C. D. HOLDSWORTH. (2007) Clinical tolerance to three 5‐aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Alimentary Pharmacology & Therapeutics 6:1, pages 51-59.
Crossref
George Earl DukesJr.Jr.. 1992. Applied Therapeutics. Applied Therapeutics 397 410 .
A. B. R. THOMSON. (2007) Review article: new developments in the use of 5‐aminosalicylic acid in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 5:5, pages 449-470.
Crossref
Charles A. Sninsky, David H. Cort, Fergus Shanahan, Bernard J. Powers, John T. Sessions, Ronald E. Pruitt, Walter H. Jacobs, Simon K. Lo, Stephan R. Targan, James J. Cerda, Daniel E. Gremillion, William J. Snape, John Sabel, Horacio Jinich, James M. Swinehart & Michael P. DeMicco. (1991) Oral Mesalamine (Asacol) for Mildly to Moderately Active Ulcerative Colitis. Annals of Internal Medicine 115:5, pages 350-355.
Crossref
Gunnar Järnerot. 1990. Inflammatory Bowel Diseases 1990. Inflammatory Bowel Diseases 1990 219 226 .
A. B. R. Thomson. 1990. Inflammatory Bowel Diseases 1990. Inflammatory Bowel Diseases 1990 179 211 .
Stephen B. Hanauer. 1990. Inflammatory Bowel Diseases 1990. Inflammatory Bowel Diseases 1990 167 177 .
G E Feurle, D Theuer, S Velasco, B A Barry, D Wordehoff, A Sommer, G Jantschek & W Kruis. (1989) Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial.. Gut 30:10, pages 1354-1361.
Crossref
S S Rao, S A Dundas, C D Holdsworth, P A Cann, K R Palmer & C L Corbett. (1989) Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.. Gut 30:5, pages 675-679.
Crossref
Malcolm G. Robinson. (1989) New Oral Salicylates in the Therapy of Chronic Idiopathic Inflammatory Bowel Disease. Gastroenterology Clinics of North America 18:1, pages 43-50.
Crossref
Kiron M. Das. (1989) Sulfasalazine Therapy in Inflammatory Bowel Disease. Gastroenterology Clinics of North America 18:1, pages 1-20.
Crossref
K.D. Rainsford. (1988) Novel non-steroidal anti-inflammatory drugs. Baillière's Clinical Rheumatology 2:2, pages 485-511.
Crossref
C D Holdsworth, S S C Rao & N W Read. (1988) Reply. Gut 29:5, pages 696-696.
Crossref
S Meyers. (1988) Olsalazine and GI transit in UC.. Gut 29:5, pages 695-696.
Crossref
S S Rao, N W Read & C D Holdsworth. (1987) Influence of olsalazine on gastrointestinal transit in ulcerative colitis.. Gut 28:11, pages 1474-1477.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.